CDK4 and cancer: Specifically, we focused on four previously-studied, targeted anti-cancer drugs for which our model includes primary targets and significant off-targets: trametinib (MEK inhibitor), alpelisib (PI-3K inhibitor), neratinib (EGFR inhibitor), and palbociclib (CDK4/6 inhibitor)54.